Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis

Bibliographic Details
Main Authors:	Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja
Format:	Online
Language:	English
Published:	Versita, Warsaw 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423757/

Similar Items

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk, Janja, et al.
Published: (2016)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
by: Mesti, Tanja, et al.
Published: (2015)

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib
by: Gavric Ana Ursula, et al.
Published: (2018-01-01)

Clonality analysis of lymphoid proliferations using the BIOMED-2 clonality assays: a single institution experience
by: Kokovic, Ira, et al.
Published: (2014)

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
by: Chen, Jing, et al.
Published: (2014)

The role of BRAF V600 mutation in melanoma
by: Ascierto, Paolo A, et al.
Published: (2012)

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
by: Wilmott, J S, et al.
Published: (2013)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
by: Ponti, Giovanni, et al.
Published: (2012)

Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection
by: Norcic, Gregor, et al.
Published: (2016)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
by: Tahiri, Andliena, et al.
Published: (2013)

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families
by: NOVAKOVIĆ, SRDJAN, et al.
Published: (2012)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
by: Sigalotti, L, et al.
Published: (2011)

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
by: Casadevall, David, et al.
Published: (2016)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
by: Sahadudheen, K., et al.
Published: (2016)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
by: Nowara, Elzbieta, et al.
Published: (2016)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
by: Sponghini, Andrea P, et al.
Published: (2015)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)

BRAF V600E-Negative Hairy Cell Leukaemia
by: Langabeer, Stephen E., et al.
Published: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
by: HE, GUOPING, et al.
Published: (2014)

Amelanotic melanoma presenting with plasmacytoid morphology and BRAF V600 mutation
by: Linda Kocovski, et al.
Published: (2015-06-01)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
by: Banzi, Maria, et al.
Published: (2016)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
by: Zepeda-Lopez, Priscilla Denise, et al.
Published: (2016)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
by: Park, Charny, et al.
Published: (2015)

Somatic V600E BRAF mutation in linear and sporadic syringocystadenoma papilliferum
by: Levinsohn, Jonathan L., et al.
Published: (2015)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
by: Simpson, Dennis A., et al.
Published: (2015)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
by: Kocovski, Linda, et al.
Published: (2015)

High frequency of BRAF V600E mutations in ameloblastoma
by: Kurppa, Kari J, et al.
Published: (2014)

BRAF V600 mutations and pathological features in Japanese melanoma patients
by: Yamazaki, Naoya, et al.
Published: (2015)

Adult classical glioblastoma with a BRAF V600E mutation
by: Takahashi, Yoshinobu, et al.
Published: (2015)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
by: GIANNINI, RICCARDO, et al.
Published: (2014)

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
by: Zaharie, Florin, et al.
Published: (2015)

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
by: ROŽMAN, SAMO, et al.
Published: (2016)

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
by: Robinson, Giles W, et al.
Published: (2014)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
by: Fedorenko, Inna V., et al.
Published: (2015)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
by: Ahn, Jun-Ho, et al.
Published: (2015)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
by: Guedes, Joana G, et al.
Published: (2013)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
by: Satzger, Imke, et al.
Published: (2015)

Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting
by: Mourah, Samia, et al.
Published: (2015)

Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream
by: Ocvirk, Janja
Published: (2010)